IN DEVELOPMENT: CB003

Cubed’s first planned compound: a stacked multiple-API formula “Ayahuasca Pill”

Illustration

DMT

Derived from plants

Illustration

Harmine MAO-i (RIMA)

A harmala alkaloid from the B. Caapi vine

DATA

Some insight into mental health data

1 in 2

The number of Canadians who will be affected by mental health issues by the age of 40

$51 Billion

Estimated annual economic burden of
mental illness in Canada

$6.8 Billion

Estimated size of psychedelic drug market 2027

59%

of Canadians approve the use of psilocybin mushrooms for terminally-ill patients

TACKLING THE MENTAL HEALTH CRISIS

A Vast Global Potential Market already used for centuries for:

DEPRESSION – ADDICTION - POST-TRAUMATIC STRESS DISORDER (PTSD)
● Growing psychedelic research & acceptance for treating depression● FDA is fast-tracking Psilocybin as a ”Breakthrough Treatment”● COVID-19 has increased mental health awareness globally
ACTIVE GOVERNMENTAL RESPONSE
● Rising Health care costs force governments to look for economic therapies● Cannabis legalization opened new regulations, infrastructure & reduces stigma● Governments leading the charge: U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) invested $27 million in psychedelics
Source: https://thedalesreport.com/psychedelics/what-the-u-s-militarys-27-million-investment-in-novel-psychedelic-type-drugs-could-mean-for-veterans